A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States

Table 3 Acute and preventive medication prescription trends among persistent (≥ 6 months) patients with a defined dose (n = 746)

	Number of prescriptions/month
	Baseline	Follow-up	P value^a
Acute medication, mean (SD)	1.89 (2.86)	1.87 (2.65)	0.816
Triptans	0.68 (1.12)	0.76 (1.18)	0.111
Ergot alkaloids	0.04 (0.41)	0.04 (0.38)	0.887
NSAID analgesics	0.39 (0.95)	0.30 (0.78)	*0.010*
Opioid analgesics	0.56 (2.06)	0.49 (1.72)	0.246
Miscellaneous	0.21 (0.73)	0.28 (1.20)	0.071
Preventive nonspecific migraine medication, mean (SD)	2.22 (2.62)	2.14 (2.48)	0.349
Anticonvulsants/antiepileptics	0.81 (1.36)	0.82 (1.40)	0.823
Antihypertensive	0.34 (0.82)	0.41 (0.99)	0.056
Muscle relaxants	0.31 (0.90)	0.30 (0.81)	0.820
Antidepressants	0.62 (1.21)	0.48 (1.02)	*0.002*
Antihistamines	0.01 (0.12)	0.01 (0.12)	0.655
OnabotulinumtoxinA	0.14 (0.52)	0.12 (0.55)	0.315

SD standard deviation, NSAID nonsteroidal anti-inflammatory drug
^aP values calculated via paired t-test; bold, italicized P values indicate statistical significance

ISSN: 1129-2377